Photo Credit: Getty/Tom Merton
The executive: Heather Bresch, CEO of Mylan
The place: District of Columbia
The controversy: Pharmaceutical company Mylan recently came under fire after it jacked up the cost of EpiPen auto injectors--prescribed for life-threatening allergies--from about $100 in 2009 to more than $600.
The timing of the price increase was subject to criticism because EpiPen;'s closest competitor, the Auvi-Q, was recently pulled from the market under a recall.
The backlash was swift and widespread, with industry experts and the public questioning the ethics of CEO Bresch and the company. Famous faces across the country took to social media to condemn the company in what became a media firestorm.
The outcome: Amid the outrage, Mylan offered a co-pay assistance program for eligible patients and unveiled a generic priced at $300, about half the cost of the EpiPen. Despite these efforts, Mylan’s response to the pricing scandal was not enough.
Critics noted that although the generic may offer financial relief, Mylan would still have an almost complete share of the market for emergency epinephrine auto injectors. In late October, company executives at pharma company Kaléo announced that the Auvi-Q would head back to market next year.
Meanwhile, CNBC reports that Congress plans to hold a hearing Nov. 30 to look into Mylan’s agreement to pay the federal government $465 million to settle potential claims that the drug company shortchanged Medicaid over rebates for sales of EpiPen.